These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26591830)

  • 1. Repositioning Generics: The Comparative Value of Liability in FDA's Proposed Rule on Labeling.
    Falcone N
    Am J Law Med; 2015; 41(2-3):483-504. PubMed ID: 26591830
    [No Abstract]   [Full Text] [Related]  

  • 2. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

  • 3. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 4. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J
    Mod Healthc; 2014 Jun; 44(26):20-2. PubMed ID: 25134408
    [No Abstract]   [Full Text] [Related]  

  • 5. Is it time to abandon FDA's no release from liability regulation for clinical studies?
    Winter JD
    Food Drug Law J; 2008; 63(2):525-36. PubMed ID: 18561476
    [No Abstract]   [Full Text] [Related]  

  • 6. Tort reform by regulation: FDA prescription drug labeling rules and preemption of state tort claims.
    Moreland MP
    J Health Life Sci Law; 2007; 1(1):39, 41-62. PubMed ID: 18610730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk, responsibility, and generic drugs.
    Kesselheim AS; Avorn J; Greene JA
    N Engl J Med; 2012 Nov; 367(18):1679-81. PubMed ID: 23113477
    [No Abstract]   [Full Text] [Related]  

  • 8. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues.
    Thomas JW
    J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021
    [No Abstract]   [Full Text] [Related]  

  • 9. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 10. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
    Rostron A
    Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 13. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 14. Bolstering the FDA's drug-safety authority.
    Schultz WB
    N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract]   [Full Text] [Related]  

  • 15. The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation.
    Morten CJ; Kesselheim AS; Ross JS
    J Law Med Ethics; 2019 Dec; 47(4):783-787. PubMed ID: 31957583
    [No Abstract]   [Full Text] [Related]  

  • 16. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA's proposed rules on patent listing requirements for new drug and 30-month stays on ANDA approval (proposed Oct. 24, 2002).
    Hui YF
    Ann Health Law; 2003; 12(2):325-40, table of contents. PubMed ID: 12856462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trying times for generic medicines in the USA.
    Lancet; 2013 Mar; 381(9872):1072. PubMed ID: 23540840
    [No Abstract]   [Full Text] [Related]  

  • 19. Authorized generics.
    Glass G
    Nat Rev Drug Discov; 2005 Dec; 4(12):953-4. PubMed ID: 16370080
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.